# A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer

> **NCT04308785** · PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 24 (actual)

## Conditions studied

- Carcinoma, Small Cell Lung

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Tiragolumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04308785
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-01
- **Primary completion:** 2023-07-25
- **Final completion:** 2023-07-25
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** The sponsor's decision was based on the negative results of SKYSCRAPER-02.
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04308785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04308785, "A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04308785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*